Protecting Neonates: Evaluating Apnea Risks and Aluminum Exposure in NICU Immunizations

Infants must breathe to live. Dr. McCullough points to SIDS as a likely result of vaccine-induced apnea.

There’s an expression in toxicology: The dose makes the poison. To which, a few years back, I added:

Body weight makes the poison.

That’s why FDA limits aluminum exposure in people with renal dysfunction to 4-5 mcg:

“Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 [micro]g/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.”

Neonates, particularly preterm infants, face unique vulnerabilities due to their developing physiology and their low body weight. A recent randomized controlled trial by Greenberg et al. underscores the need for critical evaluation of vaccination practices in neonatal intensive care units (NICUs). This trial linked vaccinations to increased episodes of apnea (temporary cessation of breathing) in premature infants in the NICU, raising questions about the safety and timing of immunizations in this population. One vaccine in question is HepB, which carries a 250 mcg dose of aluminum hydroxide via injection on Day 1 of life. Aluminum-based vaccine adjuvants have come under intense recent scrutiny due to their potential neurotoxic effects and cumulative body burden.

Evidence from the Greenberg Trial

A new study, the Greenberg trial, randomized 223 preterm infants to assess the risk of apnea following standard 2-month vaccinations. The study reported that 24% of vaccinated infants experienced at least one apnea event, compared to 10% in the unvaccinated group. Vaccination in the NICU brought an adjusted odds ratio of 2.70 (95% CI, 1.27–5.73), highlighting a clear signal of increased risk.

Though no serious adverse events were observed within the 48-hour monitoring window, the study’s design leaves unanswered questions about long-term safety and recurrence rates of apnea, particularly after hospital discharge - and the potential role of apnea due to exposures to aluminum via vaccines in full-term infants.

Total Aluminum Exposure in the NICU

Using the above data, we calculate the total aluminum exposure per vaccination session for preterm infants receiving the HepB, DTaP, PCV13, and Hib vaccines (if PedvaxHIB is used):

• Minimum Aluminum Exposure:

  • HepB (250 mcg) + DTaP (330 mcg) + PCV13 (125 mcg) = 705 mcg

• Maximum Aluminum Exposure:

  • HepB (250 mcg) + DTaP (625 mcg) + PCV13 (125 mcg) + Hib (225 mcg) = 1,225 mcg

Per-Bodyweight Aluminum Exposure for a Preterm Infant

For a preterm infant weighing 1.5 kg:

• Minimum Aluminum Exposure:

  705 mcg÷1.5 kg=470 mcg/kg

• Maximum Aluminum Exposure:

  1,225 mcg÷1.5 kg=816.7 mcg

For a smaller infant weighing 1.0 kg, the aluminum exposure would range from 705 mcg/kg (minimum) to 1,225 mcg/kg (maximum). Assuming an average length of stay (or survival) of 20 days, the average daily aluminum exposure for a NICU stay of 20 days is:

• Minimum exposure: 35.25 mcg/day

• Maximum exposure: 61.25 mcg/day

This range significantly exceeds the FDA’s recommended intravenous aluminum limit of 4–5 mcg/kg/day for individuals with impaired renal function. The implications of such high exposure levels, especially in vulnerable preterm infants, require careful consideration, further research, and potential adjustments to vaccination practices.

Aluminum Adjuvants: Pharmacokinetics and Safety Concerns

Aluminum-based adjuvants, used to enhance vaccine efficacy, contribute to an infant's cumulative aluminum exposure. A single dose of the hepatitis B vaccine, often administered in NICUs, delivers 250 mcg of aluminum. For a 1.5 kg neonate, this translates to a per-weight dose of 167 mcg/kg, far exceeding the FDA’s recommended intravenous aluminum limit of 4–5 mcg/kg/day for individuals with compromised renal function.

Studies by IPAK (Lyons-Weiler et al., 2020; McFarland et al., 2020) provided pediatric dose limits (PDLs) of aluminum that account for body weight. These limits suggest that current vaccination schedules may expose neonates to aluminum levels significantly exceeding safe thresholds. Additionally, the persistence of aluminum in tissues, including the brain, raises concerns about chronic toxicity.

Insights from Animal Models

Animal studies demonstrate that aluminum hydroxide can reliably and reproducibly induce autoimmune conditions and neuroinflammation. Research has shown that doses proportional to those used in human vaccines can trigger endoplasmic reticulum stress, activation of the unfolded protein response, and long-term immune dysregulation in rodent models. These findings call for caution in extrapolating safety from short-term human trials to long-term health outcomes.

Recommendations for NICU Practices

The interplay between vaccination benefits and potential risks in neonates requires a nuanced approach:

1. Provide True Informed Consent on Aluminum Toxicity to Parents. Parents should be in the driver’s seat when deciding the risk of exposure to aluminum hydroxide via vaccines. NICU staff should discuss this transparently with parents.

2. Aluminum-Free Alternatives:
   Vaccines that do not contain aluminum adjuvants should be prioritized, especially for premature and low-birthweight infants. To reduce cumulative aluminum exposure in neonates, developing and approving nonaluminum formulations must become a priority in public health policy.

3. Delayed Vaccination:
   For infants who are not at immediate risk of Hepatitis B infection, or who have respiratory or cardiac episodes following vaccination, delaying non-essential vaccinations until greater physiological maturity may provide a safer path forward. This approach could allow for improved aluminum clearance and reduced risk of adverse effects.

4. Weight-Based Dosing:
   Current one-size-fits-all vaccine doses fail to account for the smaller body mass and underdeveloped renal function of preterm infants. Preterm infants, particularly those under 2 kg, may receive disproportionately high aluminum exposure compared to larger infants. Weight-based dosing could mitigate this risk and align vaccination practices with established pharmacological principles.

5. Monitoring and Research:
   Longer follow-up periods and large-scale studies are necessary to evaluate the long-term impacts of neonatal vaccination schedules, including their safety and efficacy. Research should also focus on understanding the pharmacokinetics of aluminum in preterm infants and developing safer vaccine formulations.

Protecting Neonates: Evaluating Apnea Risks and Aluminum Exposure in NICU Immunizations

Preterm infants are among the most vulnerable populations in neonatal care. Their underdeveloped organs, immature immune systems, and delicate physiology demand tailored medical approaches. One of the critical areas of concern in their care is the administration of routine vaccinations, including the hepatitis B vaccine, which contains aluminum-based adjuvants. A recent study by Greenberg et al. highlighted an increased risk of apnea following vaccination in preterm infants, raising important questions about safety. Coupled with growing evidence about aluminum’s potential neurotoxicity and cumulative impact, these findings underscore the need to reassess immunization strategies for this population.

Apnea Risk in Vaccinated Preterm Infants: Insights from the Greenberg Trial

Greenberg et al. conducted a randomized clinical trial involving 223 preterm infants born before 33 weeks of gestation. The study aimed to evaluate the risk of apnea—pauses in breathing often accompanied by bradycardia—after routine vaccinations administered at 2 months of age. The findings were striking: 24% of vaccinated infants experienced at least one apnea episode compared to 10% in the unvaccinated group. Although the mean number and duration of apneic episodes were not significantly different, the adjusted odds ratio of 2.70 (95% CI, 1.27–5.73) indicated a considerable increase in apnea risk among vaccinated infants.

The study’s short follow-up period (48 hours, with exploratory monitoring up to 14 days) and the lack of mechanistic exploration leave critical questions unanswered. What drives the increased risk of apnea in vaccinated infants? Could aluminum adjuvants or immune activation be contributing factors? These questions demand urgent attention, particularly in light of broader concerns about aluminum’s safety.

Aluminum Adjuvants: A Double-Edged Sword in Vaccines

Aluminum-based adjuvants, such as aluminum hydroxide and aluminum phosphate, enhance vaccine immune responses. However, their inclusion has sparked concerns, particularly for neonates with underdeveloped detoxification systems. Unlike ingested aluminum, which is primarily excreted through the gastrointestinal tract without entering the body, injected aluminum bypasses these barriers and is fully bioavailable.

For a preterm infant weighing 1.5 kg, a single dose of the hepatitis B vaccine delivers 167 mcg/kg of aluminum—more than 30 times the FDA-recommended intravenous aluminum exposure limit of 4–5 mcg/kg/day for patients with impaired renal function. This exposure is compounded by the vaccine schedule, which includes multiple doses within the first months of life. Research by IPAK has shown that pediatric dose limits for aluminum are frequently exceeded under current vaccine guidelines, potentially exposing infants to harmful levels.

Evidence from Animal Studies: Aluminum and Autoimmunity

Animal models have demonstrated aluminum’s potential to induce autoimmunity, neuroinflammation, and systemic toxicity. Studies have shown that aluminum hydroxide can trigger endoplasmic reticulum stress, the unfolded protein response, and chronic immune activation, particularly at doses proportional to those in human vaccines. These mechanisms are linked to the disruption of neural and immune homeostasis, with implications for neurodevelopment.

Furthermore, evidence exists that aluminum hydroxide can cross the blood-brain barrier and accumulate in neural tissues. This raises concerns about its long-term impact on the developing brain, particularly in preterm infants whose neurological systems are still maturing.

Closing the Knowledge Gap: The Need for Further Research

Despite decades of aluminum use in vaccines, critical knowledge gaps remain. Longitudinal studies are needed to track the cumulative effects of aluminum exposure in preterm infants. Mechanistic research should focus on understanding how aluminum interacts with immature immune and nervous systems, particularly its role in vaccine-related apnea and neurodevelopmental outcomes.

Lyons-Weiler et al. emphasized the importance of revisiting regulatory safety standards for aluminum, particularly for injected forms. The extrapolation of dietary aluminum safety thresholds to injected aluminum has long been criticized as insufficient. This gap highlights the need for rigorous, updated evaluations that reflect the unique dynamics of vaccine adjuvants.

Conclusion

Preterm infants represent a delicate balance of risks and benefits in healthcare. While vaccination is touted as a cornerstone of public health, it is imperative to ensure its implementation prioritizes vulnerable populations' safety. The Greenberg study’s findings on apnea and mounting evidence about aluminum’s neurotoxic potential call for a reevaluation of vaccination practices in NICUs.

Citations

Greenberg RG, Rountree W, Staat MA, et al. Apnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. Published online January 06, 2025. doi:10.1001/jamapediatrics.2024.5311

Lyons-Weiler, J, G McFarland, E La Joie. 2020. Impact of catch-up vaccination on aluminum exposure due to new laws and post social distancing. J Trace Elements in Medicine and Biology, Volume 62, December 2020, 126649

McFarland, G, E La Joie, P Thomas and J Lyons-Weiler. 2020. Acute Exposure and Chronic Retention of Aluminum in Three Vaccine Schedules and Effects of Genetic and Environmental Variation. J Trace Elements in Medicine and Biology 58:126444. https://www.sciencedirect.com/science/article/pii/S0946672X19305784

Related:

BREAKING--Combination Vaccination of Premature Neonates Results in Apnea Events